The Latest Breaking News from Johnson & Johnson (

Thousands of claimants in the U.K. are suing Johnson Johnson (NYSE:JNJ), accusing the healthcare giant of knowingly selling asbestos-contaminated talcum powder that allegedly caused cancer in consumers. The case, involving roughly 3,000 individuals, is one of the largest product liability claims of its kind to reach the High Court in…

A legal claim involving 3,000 people has been reportedly filed against Johnson Johnson (NYSE:JNJ) in the U.K., alleging that the company knowingly sold asbestos-contaminated baby powder.

IN FULL

The pharmaceutical company has been accused of ‘concealing’ the risk to the public for decades

Johnson Johnson (NYSE:JNJ) on Tuesday reported better-than-expected third-quarter earnings on Tuesday.

On Tuesday, Johnson Johnson (NYSE:JNJ) reported a third-quarter 2025 adjusted earnings of $2.80 per share, up 15.7% year over year, beating the consensus of $2.75.

Johnson & Johnson (NYSE: JNJ) beat Q3 estimates, raised revenue guidance, and plans an orthopedics spin-off—analysts see up to 50% upside for JNJ stock.

Johnson Johnson (NYSE:JNJ) on Tuesday reported a third-quarter 2025 adjusted earnings of $2.80 per share, up 15.7% year over year, beating the consensus of $2.75.

With U.S. stock futures trading lower this morning on Tuesday, some of the stocks that may grab investor focus today are as follows:

Health care giant Johnson Johnson (NYSE:JNJ) has had a good year with its shares trading near all-time highs. The company looks to keep a trend of beating analyst estimates when third-quarter financial results are reported before market open Tuesday.

The Food and Drug Administration (FDA) has updated safety labeling for Johnson Johnson's (NYSE:JNJ) Carvykti after receiving reports of immune effector cell-associated enterocolitis (IEC-EC)—a rare but serious complication seen in both clinical trials and postmarketing data.